About Ambry Genetics®
Ambry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind the genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions. For more information, please visit www.ambrygen.com.
About Volpara Solutions
Volpara Solutions is committed to helping save families from cancer. Volpara's advanced technology platform combines with the healthcare provider's expertise to provide a high-quality, optimized, and personalized cancer screening experience. From the time a patient enters a clinic to when they obtain key results, our platform collects and analyzes information to better understand a patient's breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities. These capabilities are being extended to lung cancer screening. Volpara's platform is supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking, and validated by a volume of peer-reviewed publications unrivaled in the breast screening industry. For more information, visit http://www.volparasolutions.com.
Back to HCB News
